HPGC Renmintongtai Pharmaceutical Valuation

Q: What is the Fair Price of 600829 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

600829 (CN¥6.9) is trading above our estimate of [[fair value]] (CN¥3.61)

Is 600829 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 600829 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 600829 (CN¥6.9) is trading above our estimate of fair value (CN¥3.61)

Significantly Below Fair Value: 600829 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 600829?

Key metric: As 600829 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 600829. This is calculated by dividing 600829's market cap by their current earnings.
What is 600829's PE Ratio?
PE Ratio	15.5x
Earnings	CN¥257.63m
Market Cap	CN¥4.00b

600829 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	11.1x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 600829's PE Ratio compare to its peers?

The above table shows the PE ratio for 600829 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	64.4x
002462 Cachet Pharmaceutical	15.9x	n/a	CN¥3.9b
002788 Luyan PharmaLtd	9.2x	n/a	CN¥3.3b
301166 Shanghai Universal BiotechLtd	183.9x	n/a	CN¥2.6b
000705 Zhejiang Zhenyuan ShareLtd	48.7x	n/a	CN¥2.7b
600829 HPGC Renmintongtai Pharmaceutical	15.5x	n/a	CN¥4.0b

Price-To-Earnings vs Peers: 600829 is good value based on its Price-To-Earnings Ratio (15.5x) compared to the peer average (64.4x).

Price to Earnings Ratio vs Industry

How does 600829's PE Ratio compare vs other companies in the CN Healthcare Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap

No more companies available in this PE range

0 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: 600829 is good value based on its Price-To-Earnings Ratio (15.5x) compared to the CN Healthcare industry average (34.5x).

Price to Earnings Ratio vs Fair Ratio

What is 600829's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

600829 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	15.5x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 600829's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥6.7b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.53

-5.8%

-34.9%

Innovita Biological Technology

CN¥5.7b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥41.72

-2.1%

28.8%

Winner Medical

CN¥19.7b

Engages in the research and development, manufacture, and marketing of cotton-based medical dressings and medical disposables, and consumer products in China.

300888

CN¥33.90

5.4%

-14.7%